Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review

Cell Therapeutics, Inc. announced today that it has completed the submission of the New Drug Application (NDA) to the U.S. FDA for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

The details can be read here.